ARS Pharmaceuticals, Inc. Annual Report - Year Ended December 31, 2025

For investors tracking the biopharmaceutical sector, this summary offers a clear look into ARS Pharmaceuticals, Inc.'s performance, financial health, and strategic direction for the fiscal year ended December 31, 2025. This overview is based on the company's official SEC 10-K filing.

1. Business Overview ARS Pharmaceuticals, Inc. develops and commercializes treatments for severe allergic reactions. Its flagship product, Neffy, is an intranasal epinephrine spray designed for the emergency treatment of allergic reactions, including anaphylaxis. The year 2025 marked a pivotal moment for the company: Neffy achieved its first commercial sale in the U.S. in June, following FDA approval. This launch signals ARS Pharmaceuticals' significant transition from a development-stage company to a commercial entity. The company also maintains strategic collaborations, including the ALK Collaboration for specific allergic conditions, a distribution agreement with Alfresa for the Japanese market, and licensing agreements with partners like Pediatrix and Seqirus. These partnerships support broader market access and product development efforts.

2. Financial Performance ARS Pharmaceuticals reported total revenue of $15.5 million for the year ended December 31, 2025. Initial Neffy product sales, following its June launch, generated $8.2 million, while collaboration agreements and milestone payments contributed an additional $7.3 million. This represents a significant increase in revenue compared to prior years, which saw minimal product sales. Despite this revenue growth, the company reported a net loss of $112.8 million, an increase from the $95.1 million net loss in the previous year. This expanded loss reflects substantial strategic investments: $58.7 million in Research and Development (R&D) for ongoing clinical programs and pipeline advancement, and $65.3 million in Selling, General, and Administrative (SG&A) expenses to support Neffy's commercial launch and marketing. Cost of Goods Sold (COGS) for Neffy sales totaled $1.8 million, resulting in a gross profit of $6.4 million from product sales.

3. Management Discussion and Analysis (MD&A) Highlights Management emphasized 2025 as a transformative year, highlighted by Neffy's successful U.S. commercial launch in June. This milestone shifted the company from a development-stage to a commercial entity, culminating years of R&D investment. The significant revenue increase to $15.5 million, primarily from initial Neffy sales and collaboration agreements, directly reflects this transition. The expanded net loss of $112.8 million (up from $95.1 million in 2024) represents a strategic investment. This loss primarily stemmed from substantial R&D expenditures of $58.7 million to advance pipeline programs and SG&A expenses of $65.3 million to build Neffy's commercial infrastructure, launch, and marketing.

A key strategic adjustment involved finalizing obligations related to the termination of the Recordati agreement in February 2023. This allowed the company to focus resources on the U.S. market and Neffy's commercialization. Management identified challenges, including securing broad insurance coverage for Neffy and navigating a competitive market. They are actively addressing these through targeted commercial strategies. The leadership team, including CEO Alexander Fitzpatrick, President Laura Shawver, CFO Eric Karas, and Chief Commercial Officer Brian Dorsey, remained stable throughout 2025. This team provided consistent strategic direction, focusing on Neffy's successful commercialization, expanding patient access through insurance, and exploring international opportunities, all while continuing to evaluate and advance the pipeline. Management believes current liquidity, bolstered by $75.0 million in term loans, will fund operations for at least 12-18 months, supporting these strategic initiatives.

4. Financial Health As of December 31, 2025, ARS Pharmaceuticals held $85.2 million in cash and cash equivalents and $35.0 million in short-term investments, totaling a liquid asset base of $120.2 million. To strengthen its financial position and fund Neffy's commercialization and ongoing R&D, the company secured Term Loans totaling $75.0 million in September 2025. While these loans increased the company's debt burden, management believes the current cash position, combined with anticipated Neffy sales and potential milestone payments, provides sufficient liquidity to fund operations for at least the next 12-18 months.

5. Risk Factors A significant risk identified is customer concentration. Approximately 45% of anticipated Neffy product revenue and collaboration revenue is expected to come from the top three customers/partners (likely major pharmacy benefit managers or distributors). The loss of, or a significant reduction in business from, any of these key entities could materially impact revenue and financial performance. Other key risks include:

• Intense competition from established injectable epinephrine auto-injectors.
• Potential delays or failures in obtaining regulatory approvals in additional markets (e.g., Europe).
• Challenges in achieving broad market adoption and favorable insurance reimbursement for Neffy.
• Inherent risks associated with pharmaceutical product development and commercialization.

6. Competitive Position ARS Pharmaceuticals positions Neffy as a differentiated alternative to existing injectable epinephrine auto-injectors, such as EpiPen (Viatris/Pfizer) and Auvi-Q (Kaleo). Neffy's key advantage lies in its intranasal delivery. This method aims to address needle phobia and offers a more convenient and potentially less intimidating administration option for patients experiencing allergic reactions. While established players dominate the market, ARS aims to capture market share by highlighting Neffy's unique delivery mechanism and convenience, particularly for patients with needle aversion or those who prefer a non-injectable option. Initial market penetration focuses on patient segments with high unmet needs or those actively seeking alternatives.

7. Future Outlook The company's future outlook largely depends on the successful ramp-up of Neffy sales and market penetration. Key initiatives include:

• Expanding Neffy's insurance coverage with major payers.
• Increasing physician awareness and prescribing.
• Potentially pursuing regulatory approval for Neffy in the European Economic Area (EEA) and other international markets, building on previous engagement with the European Medicines Agency (EMA). Continued investment in R&D for pipeline expansion and leveraging existing collaboration agreements also remain central to long-term growth and value creation.

8. Market Trends and Regulatory Changes (Supplementary Information) The pharmaceutical market for allergic reactions is influenced by evolving insurance dynamics, including increasing pressure on drug pricing and the need for robust clinical and economic data to secure product placement on insurance plans. Regulatory scrutiny remains high, particularly for new drug approvals and post-market surveillance. The company also monitors trends in patient preference for less invasive drug delivery methods, which Neffy addresses. While no major new regulatory changes significantly impacted ARS in 2025, the ongoing regulatory processes for drug approval and reimbursement continue to shape their operational environment.